Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial

Kyoung Ho Yoon; Jae Doo Yoo; Chong Hyuk Choi; Jungsun Lee; Jin Yeon Lee; Sang Gyun Kim; Jae Young Park

doi:10.1177/1947603520921448

Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial

Kyoung Ho Yoon, Jae Doo Yoo, Chong Hyuk Choi, Jungsun Lee, Jin Yeon Lee, Sang Gyun Kim, Jae Young Park

Department of Orthopedic Surgery

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Objective: To compare the efficacy and safety of costal chondrocyte–derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design: Thirty subjects with an International Cartilage Repair Society (ICRS) grade 3 to 4 chondral defect (2-10 cm² in area; ≤4 cm³ in volume) were randomized at a ratio of 2:1 (CCP-ACI:MFx). Twenty patients were allocated in the CCP-ACI group and 10 patients in the MFx group. CCP-ACI was performed by harvesting costal cartilage at least 4 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results: MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The improvement in MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks (39.1 vs 21.8 and 43.0 vs 24.8, respectively). The proportions of complete defect repair and complete integration were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Improvement in Lysholm score and KOOS subscores, including Function (Sports and Recreational Activity) and knee-related quality of life was significantly greater in the CCP-ACI group than the MFx group at 48 weeks (35.4 vs 31.5, 35.7 vs 28.5, and 27.9 vs 11.6, respectively). Conclusion: Treatment of cartilage defects with CCP-ACI yielded satisfactory cartilage tissue repair outcomes, with good structural integration with native cartilage tissue shown by magnetic resonance imaging at 24 and 48 weeks after surgery. Level of Evidence: Level 1: Randomized controlled study.

Original language	English
Pages (from-to)	1092S-1104S
Journal	Cartilage
Volume	13
Issue number	1_suppl
DOIs	https://doi.org/10.1177/1947603520921448
State	Published - Dec 2021

Bibliographical note

Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants of the Ministry of Health & Welfare, Republic of Korea (HI15C0963). The funding source had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Biosolution Co., Ltd. provided funding for this study in the form of technical solutions, including the use of their facilities and laboratory equipment.

Publisher Copyright:
© The Author(s) 2020.

Keywords

autologous chondrocyte implantation
cartilage repair
chondral lesion
costal cartilage

Access to Document

10.1177/1947603520921448

Cite this

@article{9be96e6962014b06bb43947d3b84555e,

title = "Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial",

abstract = "Objective: To compare the efficacy and safety of costal chondrocyte–derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design: Thirty subjects with an International Cartilage Repair Society (ICRS) grade 3 to 4 chondral defect (2-10 cm2 in area; ≤4 cm3 in volume) were randomized at a ratio of 2:1 (CCP-ACI:MFx). Twenty patients were allocated in the CCP-ACI group and 10 patients in the MFx group. CCP-ACI was performed by harvesting costal cartilage at least 4 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results: MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The improvement in MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks (39.1 vs 21.8 and 43.0 vs 24.8, respectively). The proportions of complete defect repair and complete integration were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Improvement in Lysholm score and KOOS subscores, including Function (Sports and Recreational Activity) and knee-related quality of life was significantly greater in the CCP-ACI group than the MFx group at 48 weeks (35.4 vs 31.5, 35.7 vs 28.5, and 27.9 vs 11.6, respectively). Conclusion: Treatment of cartilage defects with CCP-ACI yielded satisfactory cartilage tissue repair outcomes, with good structural integration with native cartilage tissue shown by magnetic resonance imaging at 24 and 48 weeks after surgery. Level of Evidence: Level 1: Randomized controlled study.",

keywords = "autologous chondrocyte implantation, cartilage repair, chondral lesion, costal cartilage",

author = "Yoon, {Kyoung Ho} and Yoo, {Jae Doo} and Choi, {Chong Hyuk} and Jungsun Lee and Lee, {Jin Yeon} and Kim, {Sang Gyun} and Park, {Jae Young}",

note = "Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants of the Ministry of Health & Welfare, Republic of Korea (HI15C0963). The funding source had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Biosolution Co., Ltd. provided funding for this study in the form of technical solutions, including the use of their facilities and laboratory equipment. Publisher Copyright: {\textcopyright} The Author(s) 2020.",

year = "2021",

month = dec,

doi = "10.1177/1947603520921448",

language = "English",

volume = "13",

pages = "1092S--1104S",

journal = "Cartilage",

issn = "1947-6035",

publisher = "SAGE Publications Inc.",

number = "1_suppl",

}

TY - JOUR

T1 - Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects

T2 - A Prospective Randomized Trial

AU - Yoon, Kyoung Ho

AU - Yoo, Jae Doo

AU - Choi, Chong Hyuk

AU - Lee, Jungsun

AU - Lee, Jin Yeon

AU - Kim, Sang Gyun

AU - Park, Jae Young

N1 - Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by grants of the Ministry of Health & Welfare, Republic of Korea (HI15C0963). The funding source had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication. Biosolution Co., Ltd. provided funding for this study in the form of technical solutions, including the use of their facilities and laboratory equipment. Publisher Copyright: © The Author(s) 2020.

PY - 2021/12

Y1 - 2021/12

N2 - Objective: To compare the efficacy and safety of costal chondrocyte–derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design: Thirty subjects with an International Cartilage Repair Society (ICRS) grade 3 to 4 chondral defect (2-10 cm2 in area; ≤4 cm3 in volume) were randomized at a ratio of 2:1 (CCP-ACI:MFx). Twenty patients were allocated in the CCP-ACI group and 10 patients in the MFx group. CCP-ACI was performed by harvesting costal cartilage at least 4 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results: MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The improvement in MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks (39.1 vs 21.8 and 43.0 vs 24.8, respectively). The proportions of complete defect repair and complete integration were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Improvement in Lysholm score and KOOS subscores, including Function (Sports and Recreational Activity) and knee-related quality of life was significantly greater in the CCP-ACI group than the MFx group at 48 weeks (35.4 vs 31.5, 35.7 vs 28.5, and 27.9 vs 11.6, respectively). Conclusion: Treatment of cartilage defects with CCP-ACI yielded satisfactory cartilage tissue repair outcomes, with good structural integration with native cartilage tissue shown by magnetic resonance imaging at 24 and 48 weeks after surgery. Level of Evidence: Level 1: Randomized controlled study.

AB - Objective: To compare the efficacy and safety of costal chondrocyte–derived pellet-type autologous chondrocyte implantation (CCP-ACI) with microfracture (MFx) for repair of articular cartilage defects of the knee. Design: Thirty subjects with an International Cartilage Repair Society (ICRS) grade 3 to 4 chondral defect (2-10 cm2 in area; ≤4 cm3 in volume) were randomized at a ratio of 2:1 (CCP-ACI:MFx). Twenty patients were allocated in the CCP-ACI group and 10 patients in the MFx group. CCP-ACI was performed by harvesting costal cartilage at least 4 weeks before surgery. Implantation was performed without any marrow stimulation. Efficacy and safety were assessed at weeks 8, 24, and 48 after surgery according to the magnetic resonance observation of cartilage repair tissue (MOCART) score and clinical outcomes. Results: MOCART scores improved from baseline to 24 and 48 weeks postoperatively in both treatment groups. The improvement in MOCART scores in the CCP-ACI group was significantly greater than that in the MFx group at 24 and 48 weeks (39.1 vs 21.8 and 43.0 vs 24.8, respectively). The proportions of complete defect repair and complete integration were significantly higher in the CCP-ACI group than the MFx group at 48 weeks. Improvement in Lysholm score and KOOS subscores, including Function (Sports and Recreational Activity) and knee-related quality of life was significantly greater in the CCP-ACI group than the MFx group at 48 weeks (35.4 vs 31.5, 35.7 vs 28.5, and 27.9 vs 11.6, respectively). Conclusion: Treatment of cartilage defects with CCP-ACI yielded satisfactory cartilage tissue repair outcomes, with good structural integration with native cartilage tissue shown by magnetic resonance imaging at 24 and 48 weeks after surgery. Level of Evidence: Level 1: Randomized controlled study.

KW - autologous chondrocyte implantation

KW - cartilage repair

KW - chondral lesion

KW - costal cartilage

UR - http://www.scopus.com/inward/record.url?scp=85085687071&partnerID=8YFLogxK

U2 - 10.1177/1947603520921448

DO - 10.1177/1947603520921448

M3 - Article

C2 - 32476445

AN - SCOPUS:85085687071

SN - 1947-6035

VL - 13

SP - 1092S-1104S

JO - Cartilage

JF - Cartilage

IS - 1_suppl

ER -

Costal Chondrocyte–Derived Pellet-Type Autologous Chondrocyte Implantation versus Microfracture for Repair of Articular Cartilage Defects: A Prospective Randomized Trial

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this